Erasca, Inc.
ERAS
Rankning i aktier
#3407
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Aktiekurs
$14.06
Marknadsvärde
$4.92B
Förändring (1 dag)
-3.00%
Förändring (1 år)
519.16%
Land
US
Handel Erasca, Inc. (ERAS)
Kategori
Healthcare
Aktiekurshistorik för Erasca, Inc. (ERAS)
Högsta slutkurs: $14.62 den 2026-10-01
Lägsta slutkurs: $19.40 den 2021-07-01
Lägsta slutkurs: $19.40 den 2021-07-01
Aktiekurshistorik för Erasca, Inc. från 2021 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | 260.39% |
| 2025 | 24.72% |
| 2024 | 41.38% |
| 2023 | -63.49% |
| 2022 | -62.73% |
| 2021 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $530.66 | 24.44% |
US
|
|
| $230.18 | 757.28% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.66 | 9.40% |
NL
|
|
| $290.41 | 2.03% |
BE
|
